| 000 | 01886 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250517233203.0 | ||
| 264 | 0 | _c20190130 | |
| 008 | 201901s 0 0 eng d | ||
| 022 | _a2055-5822 | ||
| 024 | 7 |
_a10.1002/ehf2.12334 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSharma, Abhinav | |
| 245 | 0 | 0 |
_aLiraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. _h[electronic resource] |
| 260 |
_bESC heart failure _c12 2018 |
||
| 300 |
_a1035-1043 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aBody Weight |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aHeart Failure _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 |
_aLiraglutide _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aObesity _xcomplications |
| 650 | 0 | 4 |
_aStroke Volume _xphysiology |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aWeight Loss _xdrug effects |
| 700 | 1 | _aAmbrosy, Andrew P | |
| 700 | 1 | _aDeVore, Adam D | |
| 700 | 1 | _aMargulies, Kenneth B | |
| 700 | 1 | _aMcNulty, Steven E | |
| 700 | 1 | _aMentz, Robert J | |
| 700 | 1 | _aHernandez, Adrian F | |
| 700 | 1 | _aMichael Felker, Gary | |
| 700 | 1 | _aCooper, Lauren B | |
| 700 | 1 | _aLala, Anuradha | |
| 700 | 1 | _aVader, Justin | |
| 700 | 1 | _aGroake, John D | |
| 700 | 1 | _aBorlaug, Barry A | |
| 700 | 1 | _aVelazquez, Eric J | |
| 773 | 0 |
_tESC heart failure _gvol. 5 _gno. 6 _gp. 1035-1043 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/ehf2.12334 _zAvailable from publisher's website |
| 999 |
_c28742799 _d28742799 |
||